SOFIE Biosciences doses first patient dosed in phase 3 trials of [18F]FAPI-74, a fluorine-18 labelled radiopharmaceutical targeting FAP for patients with GI cancers: Dulles, Virgi ...

SOFIE Biosciences, an established U.S. manufacturer and developer of radiopharmaceuticals, today announced that the first patient has been dosed in one of its two Phase 3 clinical trials evaluating ...

Renal fibrosis represents a key driver of the pathology of chronic kidney disease (CKD), marked by fibroblast activation, tubular damage and inflammation. Previous work found that cyclic guanosine ...

But by a wonderful quirk of nature, this fascinating chemical compound was found to inhibit the activation of hepatic ...

Preliminary Phase 1b data is in line with Phase 1a data reported at the European Society of Medical Oncology in September 2025 ...

Chimeric antigen receptor T (CAR-T) cell therapy has revolutionized hematologic cancer treatment, but its efficacy in solid tumors remains limited by poor infiltration into the complex tumor ...

In the expanding field of peptide-based research, a combination of two bioactive molecules—BPC‑157 and TB‑500—has garnered ...

Learn more about whether Lantheus Holdings, Inc. or Omnicell, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Chimeric antigen receptor T (CAR-T) cell therapy has revolutionized hematologic cancer treatment, but its efficacy in solid tumors remains limited by ...

Thymagen (also called thymogen; dipeptide Glu-Trp, EW) is a synthetic peptide analog derived from thymic extracts and regarded in peptide bioregulator research for its putative immunoregulatory and ...